Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Chiral Quest Subsidiary Signs License Agreement with
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
VioQuest's subsidiary Chiral Quest, Inc., (VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the process development and manufacture of single-enantiomer intermediates and active pharmaceutical ingredients.
This agreement provides Merck with access to a broad range of proprietary ligands and catalysts.
